Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Immune Health Supplements Market, By Product
7.1. Immune Health Supplements Market, by Product, 2021-2030
7.1.1. Vitamin and Mineral Supplements
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Herbal Supplements
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. Probiotic Supplements
7.1.3.1. Market Revenue and Forecast (2017-2030)
7.1.4. Others
7.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Immune Health Supplements Market, By Form
8.1. Immune Health Supplements Market, by Form, 2021-2030
8.1.1. Capsules
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Tablets
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Powder
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Liquid
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Gel
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. Soft gels
8.1.6.1. Market Revenue and Forecast (2017-2030)
8.1.7. Others
8.1.7.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Immune Health Supplements Market, By Application
9.1. Immune Health Supplements Market, by Application, 2021-2030
9.1.1. Hair growth
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Gut health
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Respiratory tract infection
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Immune Health Supplements Market, By Mode Of Medication
10.1. Immune Health Supplements Market, by Mode Of Medication, 2021-2030
10.1.1. Prescription based
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Self-medication
10.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Immune Health Supplements Market, By Distribution Channel
11.1. Immune Health Supplements Market, by Distribution Channel, 2021-2030
11.1.1. Pharmacies/Drug Stores
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Supermarkets and Hypermarkets
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. E-commerce
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Immune Health Supplements Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Product (2017-2030)
12.1.2. Market Revenue and Forecast, by Form (2017-2030)
12.1.3. Market Revenue and Forecast, by Application (2017-2030)
12.1.4. Market Revenue and Forecast, by Mode Of Medication (2017-2030)
12.1.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.1.6. U.S.
12.1.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Form (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Application (2017-2030)
12.1.6.4. Market Revenue and Forecast, by Mode Of Medication (2017-2030)
12.1.6.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.1.7. Rest of North America
12.1.7.1. Market Revenue and Forecast, by Product (2017-2030)
12.1.7.2. Market Revenue and Forecast, by Form (2017-2030)
12.1.7.3. Market Revenue and Forecast, by Application (2017-2030)
12.1.7.4. Market Revenue and Forecast, by Mode Of Medication (2017-2030)
12.1.7.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.2. Market Revenue and Forecast, by Form (2017-2030)
12.2.3. Market Revenue and Forecast, by Application (2017-2030)
12.2.4. Market Revenue and Forecast, by Mode Of Medication (2017-2030)
12.2.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.6. UK
12.2.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Form (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Application (2017-2030)
12.2.6.4. Market Revenue and Forecast, by Mode Of Medication (2017-2030)
12.2.6.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.7. Germany
12.2.7.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.7.2. Market Revenue and Forecast, by Form (2017-2030)
12.2.7.3. Market Revenue and Forecast, by Application (2017-2030)
12.2.7.4. Market Revenue and Forecast, by Mode Of Medication (2017-2030)
12.2.7.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.8. France
12.2.8.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.8.2. Market Revenue and Forecast, by Form (2017-2030)
12.2.8.3. Market Revenue and Forecast, by Application (2017-2030)
12.2.8.4. Market Revenue and Forecast, by Mode Of Medication (2017-2030)
12.2.8.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.9. Rest of Europe
12.2.9.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.9.2. Market Revenue and Forecast, by Form (2017-2030)
12.2.9.3. Market Revenue and Forecast, by Application (2017-2030)
12.2.9.4. Market Revenue and Forecast, by Mode Of Medication (2017-2030)
12.2.9.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.2. Market Revenue and Forecast, by Form (2017-2030)
12.3.3. Market Revenue and Forecast, by Application (2017-2030)
12.3.4. Market Revenue and Forecast, by Mode Of Medication (2017-2030)
12.3.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.6. India
12.3.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Form (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Application (2017-2030)
12.3.6.4. Market Revenue and Forecast, by Mode Of Medication (2017-2030)
12.3.6.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.7. China
12.3.7.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.7.2. Market Revenue and Forecast, by Form (2017-2030)
12.3.7.3. Market Revenue and Forecast, by Application (2017-2030)
12.3.7.4. Market Revenue and Forecast, by Mode Of Medication (2017-2030)
12.3.7.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.8. Japan
12.3.8.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Form (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Application (2017-2030)
12.3.8.4. Market Revenue and Forecast, by Mode Of Medication (2017-2030)
12.3.8.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.9. Rest of APAC
12.3.9.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.9.2. Market Revenue and Forecast, by Form (2017-2030)
12.3.9.3. Market Revenue and Forecast, by Application (2017-2030)
12.3.9.4. Market Revenue and Forecast, by Mode Of Medication (2017-2030)
12.3.9.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.2. Market Revenue and Forecast, by Form (2017-2030)
12.4.3. Market Revenue and Forecast, by Application (2017-2030)
12.4.4. Market Revenue and Forecast, by Mode Of Medication (2017-2030)
12.4.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.6. GCC
12.4.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Form (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Application (2017-2030)
12.4.6.4. Market Revenue and Forecast, by Mode Of Medication (2017-2030)
12.4.6.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.7. North Africa
12.4.7.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.7.2. Market Revenue and Forecast, by Form (2017-2030)
12.4.7.3. Market Revenue and Forecast, by Application (2017-2030)
12.4.7.4. Market Revenue and Forecast, by Mode Of Medication (2017-2030)
12.4.7.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.8. South Africa
12.4.8.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Form (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Application (2017-2030)
12.4.8.4. Market Revenue and Forecast, by Mode Of Medication (2017-2030)
12.4.8.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.9. Rest of MEA
12.4.9.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.9.2. Market Revenue and Forecast, by Form (2017-2030)
12.4.9.3. Market Revenue and Forecast, by Application (2017-2030)
12.4.9.4. Market Revenue and Forecast, by Mode Of Medication (2017-2030)
12.4.9.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product (2017-2030)
12.5.2. Market Revenue and Forecast, by Form (2017-2030)
12.5.3. Market Revenue and Forecast, by Application (2017-2030)
12.5.4. Market Revenue and Forecast, by Mode Of Medication (2017-2030)
12.5.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5.6. Brazil
12.5.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Form (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Application (2017-2030)
12.5.6.4. Market Revenue and Forecast, by Mode Of Medication (2017-2030)
12.5.6.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5.7. Rest of LATAM
12.5.7.1. Market Revenue and Forecast, by Product (2017-2030)
12.5.7.2. Market Revenue and Forecast, by Form (2017-2030)
12.5.7.3. Market Revenue and Forecast, by Application (2017-2030)
12.5.7.4. Market Revenue and Forecast, by Mode Of Medication (2017-2030)
12.5.7.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 13. Company Profiles
13.1. Bayer AG
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Pfizer Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Sun Pharmaceutical Industries Limited
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Swisse Wellness Pty Ltd.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. GlaxoSmithKline Inc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Abbott Laboratories
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Amway Corp.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. The Nature's Bounty Co.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Herbalife Nutrition of America, Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Himalaya Global Holdings Ltd.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
13.11. American Health
13.11.1. Company Overview
13.11.2. Product Offerings
13.11.3. Financial Performance
13.11.4. Recent Initiatives
13.12. Unilever
13.12.1. Company Overview
13.12.2. Product Offerings
13.12.3. Financial Performance
13.12.4. Recent Initiatives
13.13. Sanofi
13.13.1. Company Overview
13.13.2. Product Offerings
13.13.3. Financial Performance
13.13.4. Recent Initiatives
13.14. Novartis
13.14.1. Company Overview
13.14.2. Product Offerings
13.14.3. Financial Performance
13.14.4. Recent Initiatives
13.15. Boehringer Ingelheim
13.15.1. Company Overview
13.15.2. Product Offerings
13.15.3. Financial Performance
13.15.4. Recent Initiatives
13.16. Nestlè
13.16.1. Company Overview
13.16.2. Product Offerings
13.16.3. Financial Performance
13.16.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms